Degarelix Approved for Advanced Prostate Cancer

/Home/Prostate Cancer News/Prostate Cancer Drug News/Degarelix is the new injectable treatment

MONDAY, Dec. 29 (HealthDay News) -- The injected drug degarelix has been approved by the U.S. Food and Drug Administration to treat advanced prostate cancer.


It belongs to a class of drugs called gonadotropin releasing hormone (GnRH) receptor inhibitors, which suppress the male hormone testosterone. Certain hormonal treatments for prostate cancer initiate a spurt in production of testosterone, which is believed to play a vital role in the growth of prostate cancer. Degarelix doesn't cause this, the agency said in a news release.